BN
|
HealthAI Desk•5 views

RSV Season Delay: 48 States Extend Infant Immunization Through April

Respiratory syncytial virus (RSV) is spreading later into spring in the U.S., with test positivity rates higher than last year. In response, 48 jurisdictions have extended immunization periods for infants through April using monoclonal antibodies. Experts highlight this data-driven approach to reduce infant hospitalizations, as RSV is a leading cause of severe illness in young children. Ten areas with year-round RSV or no supporting data did not extend the period. Monoclonal antibodies have shown effectiveness in lowering hospitalization rates during their third season of use. Health officials emphasize the importance of surveillance and timely immunization to combat ongoing transmission.

Ad slot
RSV Season Delay: 48 States Extend Infant Immunization Through April

Respiratory syncytial virus (RSV) is spreading later into spring than usual, leading 48 U.S. jurisdictions to extend immunization periods for infants through April to reduce hospitalizations.

Extended Immunization Periods

  • 48 out of 66 federally funded immunization programs have extended the RSV immunization window through April 30.
  • This extension allows continued ordering of monoclonal antibodies via the Vaccines for Children program.
  • Ten jurisdictions, including Florida and Hawaii, did not extend due to year-round RSV seasons or insufficient data.

RSV Season Trends

  • For the third week of March, RSV test positivity was 7.5%, higher than 5% at the same time last year.
  • RSV typically peaks in winter but this year peaked later, with activity lingering into spring.
  • Experts note that shifts may be due to environmental, biological, or behavioral factors, but exact reasons are unknown.
Ad slot

Expert Insights

  • Dr. Susan Kansagra: "RSV peaked later... health departments are recommending monoclonal antibody administration into April."
  • Dr. Michelle Fiscus: Calls RSV immunizations "game-changers" for preventing infant hospitalizations.
  • Dr. Jennifer Nuzzo: Emphasizes the need for real-time surveillance to tie responses to disease trends, not fixed calendars.

Importance of Monoclonal Antibodies

  • Monoclonal antibodies provide passive immunity and are recommended for infants and some young children.
  • A CDC study showed lower hospitalization rates in infants up to 7 months during the 2024-25 season compared to previous seasons.
  • This is the third season these antibodies are available, marking a significant advancement in RSV prevention.

State Responses and Data

  • Washington state saw RSV activity increase in December, over a month later than usual.
  • Louisiana and Washington, D.C., decided against extensions; Missouri and Virginia will consider cases individually.
  • The Association of Immunization Managers coordinated with jurisdictions to assess local data.

Conclusion

  • The extension aims to protect newborns, with 10,000 babies born daily in the U.S.
  • Health officials stress continuing immunizations while RSV circulation remains high.
  • Despite inquiries into RSV shots, documented safety and efficacy support their use.
Ad slot